Vivesto AB · OMXSTO:VIVE
Vivesto AB — Oasmia Pharmaceutical — Investor Presentation (June 2020)
19 slides from Vivesto AB's investor presentation, June 2020
Slide 1: Oasmia Pharmaceutical AB Company Presentation
OASMIA PHARMACEUTICAL AB COMPANY PRESENTATION NON-CONFIDENTIAL F. R. Martelet, M.D. CEO June 2020 NON-CONFIDENTIAL 1
Slide 2: Forward looking statement
Forward looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Contents
Contents Introduction - 4 Oasmia: Senior Management and Board of Directors - 5 Encapsulation technology and Oasmia’s XR17™ platform - 6 Oasmia’s product portfolio - 11 Apealea® – offering improved treatment options in ovarian cancer patients – 13 Global partner - 16 Oasmia’s Strategic vision - 19 NO
Slide 4: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company Founded in 1999 NASDAQ Stockholm 2010 HQ Uppsala, Sweden Market Cap approx. SEK 3,1 B 27 employees XR17™ technology platform, allowing nano-sized particle GMP-certified Production formulations of APIs, to be soluble in Facility and R&D,
Slide 5: New CEO and experienced management team and Board taking Oasmia to next level
New CEO and experienced management team and Board taking Oasmia to next level FRANCOIS MARTELET, M.D., MICHAEL AF ELIN TRAMPE, Master’s Degree Business WINKLERFELT Chief Technical Officer Chief Executive Officer Chief Finance Officer Previous experience: CEO in Biotechnology/ BioPharma in UK, DNK, U
Slide 6: Encapsulation technologies as drug delivery systems
Encapsulation technologies as drug delivery systems Advantages of 3 clinically established encapsulation technologies • Improving the stability of hydrophobic drugs, making them suitable for administration • Improving biodistribution and pharmacokinetics leading to better efficacy • Improving patien
Slide 7: Oasmia's XR17 increases solubility and potentially improves safety of new formulations
Oasmia’s XR17™ increases solubility and potentially improves safety of new formulations LOW WATER SOLUBILITY AFFECTS SOLUBILITY ENHANCERS CAN CAUSE C.40% OF APPROVED DRUGS AND SERIOUS ADVERSE SIDE EFFECTS OR C.90% OF PIPELINE DRUGS1 REQUIRE USE OF ADDITIONAL DRUGS1 API2 XR17™ XR17™ + API2 Hydrophili
Slide 8: XR17 – multiple opportunities in oncology, human and animal health
XR17TM – multiple opportunities in oncology, human and animal health XR17™ ANIMAL ONCOLOGY OTHER HEALTH Therapeutic Areas Lung Cervical cancer cancer Prostate Breast Ovarian Bladder cancer cancer cancer cancer NON-CONFIDENTIAL 8
Slide 9: XR17 – Key platform benefits
XR17™ – Key platform benefits Strong solubilization • Superior solubility compared to other nanoparticle capacity platforms and technologies Strong & validated • Clinically validated safety profile • Significantly reduce the need for premedication Drug load • Drug load capacity (API to cosolvent rat
Slide 10: XR17 – clear benefits for patients
XR17™ – clear benefits for patients NOVEL XR17TM PLATFORM PROVEN CLINICAL ADVANTAGES Based on vitamin A derivatives Demonstrated safety in cancer Forms micelles, 10 – 60 nm size indication1 High API-to-carrier ratio potentially reduces risk of unwanted carrier biological Shorter infusion time1,2 eff
Slide 11: XR17 – broad IP protection worldwide up to 2036
XR17™ – broad IP protection worldwide up to 2036 PROCESS WATER-INSOLUBLE ANTICANCER COMPOSITIONS Protects the manufacturing Protects poorly water-soluble Protects XR17™ in combination process for XR17™ APIs1 in combination with XR17™ with chemotherapeutic agents PCT 57 6 patents granted patents gran
Slide 12: Building a diverse human health portfolio based on XR17 platform technology
Building a diverse human health portfolio based on XR17™ platform technology Registration / Product Indication Pre-clinical Phase I Phase II Phase III approval Geography Ovarian cancer Pre-NDA meeting USA Ovarian cancer EU / EEA1 Apealea® / Paclical® Ovarian cancer Russia (paclitaxel) Ovarian cancer
Slide 13: Oasmia Pharmaceutical AB Animal Health Portfolio
Oasmia Pharmaceutical AB Animal Health Portfolio Registration / Product Indication Pre-clinical Clinical approval Geography Paccal vet Mammary (paclitaxel) Carcinoma No US (Canines) Doxophos vet Lymphoma (doxorubicin) No US (Canines) Doxophos vet Paccal vet Potential next steps Potential Next steps
Slide 14: Apealea – offering improved treatment options
Apealea® – offering improved treatment options Approved in Current standard of care in Ovarian cancer is EU/EEA for carboplatin + paclitaxel treatment of first relapse ovarian Subset of patients cannot tolerate solvent-based cancer1 and in paclitaxel Russia for first line and relapsed Apealea® is an
Slide 15: Apealea – meeting unmet medical needs in selected ovarian cancer patients
Apealea® – meeting unmet medical needs in selected ovarian cancer patients OVARIAN CANCER INCIDENCE1 70000 66300 295,000 women were diagnosed with ovarian cancer 60000 in 2018 – the 8th most common cancer type in women1 50000 Approximately 70% of women Incidence 40000 have a returning disease within
Slide 16: Differentiation vs Abraxane and other paclitaxel products
Differentiation vs Abraxane and other paclitaxel products Genexol-PM® Product Apealea® Taxol® Abraxane® Lipusu® Korea Apealea® is the only non- Company Oasmia BMS Celgene Luye Samyang cremophor drug Ovarian Cancer Ovarian Cancer Ovarian Cancer approved for use Indication Ovarian Cancer Breast Cancer
Slide 17: Apealea – global partnership worth up to $698m + royalties
Apealea® – global partnership worth up to $698m + royalties Agreement with US-based Elevar Therapeutics, subsidiary of South Korea’s HLB Upfront payment $20M Double digit royalties on global Apealea® sales % Milestones based on regulatory and sales achievements $678M Oasmia retains sole control over
Slide 18: Key value drivers
Key value drivers Short Term 12 months Mid Term 12-24 months • Docetaxel micellar clinical • Apealea Royalties development plan • Docetaxel micellar Phase 1 • Phase 1 Study Initiation Study Results • Review of Animal Health • Realisation of cost control Business assets measures • XR-17 Technology Pl
Slide 19: Strategic vision: Oasmia to become a significant speciality pharma Co.
Strategic vision: Oasmia to become a significant speciality pharma Co. Platform to build a Sweden-based cash-flow positive specialty pharma • Proven ability to register an oncology drug leader • Expand pipeline, including XR17™ technology • Strong cash position • Proven ability to negotiate substant
Oasmia Pharmaceutical — Investor Presentation (June 2020) on 6ix